Article Text

Download PDFPDF
Letter response
Response to Dr Bolland's eLetter: Strontium and cardiovascular events
  1. Jean Yves Reginster
  1. Correspondence to Professor Jean Yves Reginster, Department of Public Health Sciences, Bone and Cartilage Metabolism Unit, State University of Liège, CHU Centre Ville +9, 45 Quai Godefroid Kurth, Liège 4020, Belgium; jyreginster{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The work carried out by the authors on calcium and the cardiovascular risk is of primary importance.1 We thank the authors for questions and comments on the Strontium ranelate Efficacy in Knee OsteoarthrItis trIAl (SEKOIA) study, safety being a primary concern for us.2

The number of emergent adverse events reported in the SEKOIA study was similar in the three treatment groups: 85.8%, 87.9% and 86.5% in the SrRan 1g, SrRan 2g and placebo groups, as well as the number of serious emergent adverse events: 17.0%, 16.5% and 17.4%, respectively. The adverse reactions …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Electronic pages
    Mark J Bolland Andrew Grey